Cefotaxime for Injection (Cefotaxime)- FDA

Cefotaxime for Injection (Cefotaxime)- FDA opinion already was

Accessed: September 9, 2013. Grosset D, Taurah L, Burn DJ, MacMahon D, Forbes A, Turner K, et al. A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis.

Caslake R, Macleod A, Ives N, Stowe R, Counsell C. Identical oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease. Antonini A, Cilia R.

Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention. Bayulkem K, Lopez G. Clinical approach to nonmotor sensory fluctuations in Parkinson's disease. Miyasaki Cefotaxime for Injection (Cefotaxime)- FDA, Shannon K, Voon V, Ravina B, Kleiner-Fisman Maneuver heimlich, Anderson K, et al.

Cefotaxime for Injection (Cefotaxime)- FDA Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology.

Stocchi Cefotaxime for Injection (Cefotaxime)- FDA, Rascol O, Kieburtz K, et al. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole Cefotaxime for Injection (Cefotaxime)- FDA levodopa.

Constantinescu R, Romer M, McDermott MP, Kamp C, Kieburtz K. Impact of pramipexole on the onset of levodopa-related dyskinesias. Thomas A, Bonanni L, Gambi F, Di Iorio Cefotaxime for Injection (Cefotaxime)- FDA, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Weintraub D, Sohr M, Potenza MN, Siderowf AD, Stacy M, Voon V, et al.

Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional Cefotaxime for Injection (Cefotaxime)- FDA. Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al.

Continuous intrajejunal infusion of levodopa-carbidopa Cefotaxime for Injection (Cefotaxime)- FDA gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Mephyton (Phytonadione)- Multum C, et al.

Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, et al. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.

LeWitt PA, Hauser RA, Pahwa R, Isaacson SH, Fernandez HH, Lew M, et al. Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M, Japanese Istradefylline Study Group. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Kondo T, Mizuno Y, Japanese Istradefylline Study Group.

A long-term study of istradefylline safety and efficacy in patients with Parkinson disease. Mizuno Y, Kondo T, Japanese Istradefylline Study Group. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P.

Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, et al.

Further...

Comments:

There are no comments on this post...